Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 8,374 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 5:13 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood

NCT02142569
View directory record Official record
Conditions
Cholesterol Lowering
Interventions
Sugar Pill, Chinese Red Yeast Rice (CRYR), CRYR + TRF, Tocotrienol-enriched Fraction of Palm Oil (TRF)
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)

NCT02568722
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Standard RRT initiation, Accelerated RRT initiation
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
3,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 26, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Iron Parameters in Non-anemic First Trimester Gravidas

NCT03670537
View directory record Official record
Conditions
Iron Deficiency (Without Anemia), Pregnancy
Interventions
Iron parameters
Diagnostic Test
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 26, 2026, 5:13 AM EDT
Withdrawn Phase 2 Interventional

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

NCT00408772
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation
Biological · Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00117975
View directory record Official record
Conditions
Lymphoma
Interventions
galiximab, rituximab
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
68
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Hollywood, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

NCT00323739
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab, RAD001
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Fort Myers, Florida • Gainesville, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

NCT02169219
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Glucocorticoids, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT03478930
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Transgender Estradiol Affirming Therapy

NCT05010707
View directory record Official record
Conditions
Transgenderism
Interventions
Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone
Drug · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 26, 2026, 5:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01015664
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
temsirolimus, cisplatin, cetuximab
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 26, 2026, 5:13 AM EDT
Completed No phase listed Observational

Correlation Salivary Cortisol and Free Serum Cortisol to Total Serum Cortisol in MICU Septic Shock

NCT00523198
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 26, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biologic Predictors of Leiomyoma Treatment Outcomes

NCT01936493
View directory record Official record
Conditions
Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
DNA analysis, Hormonal analysis
Genetic · Other
Lead sponsor
Elizabeth A. Stewart
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 26, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Omalizumab Before Onset of Exacerbations

NCT05332067
View directory record Official record
Conditions
Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 26, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

Rituximab to Prevent Recurrence of Proteinuria

NCT01164098
View directory record Official record
Conditions
FSGS, Proteinuria
Interventions
Rituximab
Drug
Lead sponsor
George W. Burke
Other
Eligibility
7 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

NCT04002401
View directory record Official record
Conditions
Refractory Large B-cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Rituximab, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Gilbert, Arizona • Duarte, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462928
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 26, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

NCT00427336
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Fludarabine, Cyclophosphamide, Antithymocyte Globulin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 26, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

NCT04099836
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 26, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

NCT00006436
View directory record Official record
Conditions
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions
Rituximab, Filgrastim, EPOCH
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 26, 2026, 5:13 AM EDT